The HYI Knouckout A-549 Polyclonal Cells product consists of a CRISPR/Cas9-edited polyclonal knockout cell population derived from the A-549 human lung adenocarcinoma epithelial cell line. This pool contains a heterogeneous collection of A-549 cells harboring targeted disruptions in the HYI gene, introduced by CRISPR/Cas9-mediated genome editing, leading to loss of hydroxypyruvate isomerase function. As a polyclonal population, it avoids the potential biases of single-cell cloning and provides a genetically diverse knockout model ideal for bulk functional assays and studies where clonal uniformity is not required.
The parental A-549 cell line originates from a 58-year-old male with lung carcinoma and is widely employed as an in vitro model for alveolar basal epithelial cells, particularly type II pneumocytes. These adherent cells carry a KRAS G12S activating mutation, which constitutively engages downstream oncogenic signaling cascades. This mutation, coupled with the lung adenocarcinoma context, makes A-549 a fitting host for examining metabolic enzyme function in cancer, as KRAS-driven tumors often exhibit altered nutrient utilization and metabolic pathway activity.
HYI encodes hydroxypyruvate isomerase, which catalyzes the isomerization of hydroxypyruvate to 2-hydroxy-3-oxopropanoate within the glyoxylate and dicarboxylate metabolism pathway. This enzymatic step is positioned upstream of important metabolites, including glycolate, glyoxylate, and oxalate, and genetically intersects with other critical pathway components such as GRHPR, AGXT, and HOGA1. While direct upstream regulators of HYI remain undefined, PPAR signaling has been suggested as a potential modulator of expression. Disruption of HYI is expected to perturb glyoxylate pathway flux, potentially altering steady-state levels of these metabolites and associated metabolic networks.
In the A-549 lung adenocarcinoma model, ablation of HYI offers a system for interrogating the interplay between glyoxylate metabolism and KRAS-driven oncogenic signaling. Cancer cells frequently reprogram metabolic pathways to support proliferation, and hydroxypyruvate isomerase may play a role in this rewiring. Loss of HYI in A-549 cells enables investigation of how glyoxylate-derived metabolites affect redox homeostasis and biosynthetic demands in a tumor-relevant context. Furthermore, because A-549 cells retain features of alveolar type II cells, they provide insights into lung epithelial handling of glyoxylate and oxalate under both normal and transformed states.
This knockout cell population is suitable for multiple experimental approaches, including HPLC-based quantitation of glyoxylate and oxalate, untargeted metabolomics, hydroxypyruvate isomerase activity assays, gene expression analysis by RT-qPCR, and western blotting. Cell viability assays under conditions of metabolic stress can reveal whether HYI loss confers sensitivity to nutrient limitation or metabolic inhibitors, highlighting potential therapeutic vulnerabilities. Collectively, the HYI Knouckout A-549 Polyclonal Cells provide a versatile resource for studying glyoxylate metabolism in cancer and metabolic disorders. For further details, please contact Ascent Research.
